Ultragenyx Pharmaceutical Inc (RARE)
43.24
-0.06
(-0.14%)
USD |
NASDAQ |
May 02, 16:00
42.20
-1.04
(-2.41%)
After-Hours: 16:24
Ultragenyx Pharmaceutical Revenue (Quarterly): 127.39M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 127.39M |
| September 30, 2023 | 98.05M |
| June 30, 2023 | 108.31M |
| March 31, 2023 | 100.50M |
| December 31, 2022 | 103.35M |
| September 30, 2022 | 90.70M |
| June 30, 2022 | 89.34M |
| March 31, 2022 | 79.94M |
| December 31, 2021 | 83.39M |
| September 30, 2021 | 81.65M |
| June 30, 2021 | 86.98M |
| March 31, 2021 | 99.40M |
| December 31, 2020 | 91.54M |
| September 30, 2020 | 81.47M |
| June 30, 2020 | 61.71M |
| March 31, 2020 | 36.31M |
| Date | Value |
|---|---|
| December 31, 2019 | 35.59M |
| September 30, 2019 | 25.80M |
| June 30, 2019 | 24.15M |
| March 31, 2019 | 18.17M |
| December 31, 2018 | 16.26M |
| September 30, 2018 | 11.76M |
| June 30, 2018 | 12.79M |
| March 31, 2018 | 10.68M |
| December 31, 2017 | 2.414M |
| September 30, 2017 | 0.198M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.005M |
| September 30, 2016 | 0.111M |
| June 30, 2016 | 0.017M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
24.15M
Minimum
Jun 2019
127.39M
Maximum
Dec 2023
79.24M
Average
86.98M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 135.40M |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 396.78M |
| FibroGen Inc | 27.14M |
| Rocket Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -123.19M |
| Total Expenses (Quarterly) | 249.44M |
| EPS Diluted (Quarterly) | -1.52 |
| Enterprise Value | 2.988B |
| Gross Profit Margin (Quarterly) | 90.54% |
| Profit Margin (Quarterly) | -96.70% |
| Earnings Yield | -19.26% |
| Normalized Earnings Yield | -19.28 |